Category: Research/Reports

Manufacturer Refunds to 340B Providers Have Steadily Increased Since 2019, Says Analysis

April 9, 2024 Rich Daly, Editor in Chief Views

An analysis from the law firm Spencer Fane found that 340B refunds have been concentrated among certain manufacturers and drugs.

A recent analysis of the increasing annual total number of drug manufacturer refunds to 340B covered entities notes they are [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Contract Pharmacies Have Proliferated, Conservative Group Says, Citing Data from Pharma-Funded Think Tank

April 4, 2024 Rich Daly, Editor in Chief Views

A Paragon Health Institute analysis found the share of 340B contract pharmacies per covered entity has increased in recent years.

Active 340B contract pharmacies reached 17,250 in 2024, according to a conservative think tank using data collected by another group funded by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Estimated 340B Revenue Exceeded Charity Care Spending for 85% of DSH Hospitals, Says Pharma-backed Group

April 2, 2024 Rich Daly, Editor in Chief Views

340B revenue exceeds charity care spending for most DSH hospitals, said a report from drug industry-backed AIR340B.

Eighty-five percent of DSH hospitals earned more in estimated 340B revenue in 2022 than they incurred in charity care costs, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Gaps in Hospital Financial Data Limit 340B Transparency, Analysis Says

March 28, 2024 William Newton, Associate Editor/Senior Writer Views

A KFF issue brief examined gaps in available data on hospitals and health systems' finances and use of the 340B program.

Significant gaps in hospital and health system’s financial data, including 340B program use, “limit transparency for policymakers, researchers, and consumers,” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Influential House GOP Group Calls for Major Medicaid Cuts and 340B Revenue to ‘Go Where Intended’

March 26, 2024 William Newton, Associate Editor/Senior Writer Views

The Republican Study Committee's proposed fiscal year 2025 budget includes calls for changes to the 340B program.

An influential conservative congressional caucus is urging Congress to significantly cut Medicaid spending and “ to ensure that drug discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Reports Critique Financial Dynamics of 340B Program

March 19, 2024 William Newton, Associate Editor/Senior Writer Views

Recent reports from 46brooklyn, a nonprofit think tank, and IQVIA, a drug industry analytics firm, criticized the financial dynamics of 340B.

The 340B program may increase medication costs for self-insured employers, a recent study from a pharmaceutical industry outsourcing and analytics [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence

March 19, 2024 Rich Daly, Editor in Chief Views

Dr. Kassem Faraj and his co-authors at the University of Michigan found 340B was associated with better treatment adherence for more vulnerable prostate cancer patients.

Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report

March 14, 2024 Rich Daly, Editor in Chief Views

340B drug discounts only amounted to a small percentage of total drugmaker revenue, a hospital-funded study found.

Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

U.C. Berkeley Researcher Proposes 340B Be Limited to the Indigent or that Providers Pass on their Discounts to Insurance Industry

March 14, 2024 Rich Daly, Editor in Chief Views

Dr. James Robinson, a health economist at University of California at Berkley, criticized hospitals’ “buy and bill” drug acquisition process.

A University of California at Berkeley academic is proposing a series of major reforms to the 340B discount drug program [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

DSH Hospitals Are Using 340B in ‘Margin-Motivated Ways,’ Says Research Review

February 27, 2024 Rich Daly, Editor in Chief Views

A recent Milbank Quarterly research review suggested DSH hospitals participate in 340B in "margin-motivated ways."

The highest-quality evidence from published 340B research indicates nonprofit, disproportionate share hospitals may be using the 340B program in margin-motivated [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live